Diagnosis and management of drug-associated interstitial lung disease.
Symptoms of drug-associated interstitial lung disease (ILD) are nonspecific and can be difficult to distinguish from a number of illnesses that commonly occur in patients with non-small-cell lung cancer (NSCLC) on therapy. Identification of drug involvement and differentiation from other illnesses is problematic, although radiological manifestations and clinical tests enable many of the alternative causes of symptoms in advanced NSCLC to be excluded. In lung cancer patients, high-resolution computed tomography (HRCT) is more sensitive than a chest radiograph in evaluating the severity and progression of parenchymal lung disease. Indeed, the use of HRCT imaging has led to the recognition of many distinct patterns of lung involvement and, along with clinical signs and symptoms, helps to predict both outcome and response to treatment. This manuscript outlines the radiology of drug-associated ILD and its differential diagnosis in NSCLC. An algorithm that uses clinical tests to exclude alternative diagnoses is also described.
Müller
N L
NL
Department of Radiology, Vancouver General Hospital and University of British Columbia, Vancouver, British Columbia, Canada. nmuller@vanhosp.bc.ca
White
D A
DA
Jiang
H
H
Gemma
A
A
D000465:Algorithms; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects* / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000150:complications* / Q000188:drug therapy; D003937:Diagnosis, Differential; D018450:Disease Progression; D006801:Humans; D017563:Lung Diseases, Interstitial / Q000139:chemically induced / Q000175:diagnosis* / Q000628:therapy*; D008175:Lung Neoplasms / Q000150:complications* / Q000188:drug therapy; D013902:Radiography, Thoracic; D014057:Tomography, X-Ray Computed